SCHEMBL799063

SCHEMBL799063

Cc1cc(NC(=O)OC(C)(C)C)n(CCOCc2ccccc2)n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 2/20 0.47
CYP2C9 P11712 1/20 0.45
PTGER1 P34995 1/20 0.45
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
GAA P10253 2/20 0.43
ALDH1A1 P00352 2/20 0.43
PPARG P37231 1/20 0.43
LMNA P02545 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
CTSS P25774 1/20 0.42
KCNJ6 P48051 2/20 0.41
KCNJ5 P48544 2/20 0.41
KCNJ3 P48549 2/20 0.41
BRD4 O60885 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
BRD9 Q9H8M2 1/20 0.39
POLB P06746 1/20 0.39
PKM P14618 1/20 0.39
NR3C1 P04150 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25594884 0.88 PPARA (0.45) PPARACYP2C9PTGER1PPARGCTSS
SCHEMBL25599482 0.87 PPARA (0.44) PPARACYP2C9PTGER1PPARGCTSS
SCHEMBL28632711 0.86 PPARA (0.42) PPARACYP2C9PTGER1KMT2AGAA
SCHEMBL798842 0.79 GAA (0.49) PTGER1MEN1KMT2AGAAALDH1A1
SCHEMBL798561 0.77 GRN (0.49) MEN1KMT2AGAAALDH1A1L3MBTL1
SCHEMBL799021 0.76 GAA (0.44) MEN1KMT2AGAAALDH1A1LMNA
SCHEMBL17517053 0.74 PKM (0.49) PPARACYP2C9PTGER1MEN1KMT2A
SCHEMBL20418814 0.74 LMNA (0.61) MEN1KMT2AGAAALDH1A1LMNA
SCHEMBL35210874 0.73 SMN1; SMN2 (0.57) PTGER1MEN1KMT2AGAABRD9
SCHEMBL22150499 0.73 TDP1 (0.41) MEN1KMT2AGAAALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9650371-B2 Sulfur-containing heterocyclic derivative having beta secretase inhibitory activity SHIONOGI & CO., LTD. (JP) 2017-05-16 US disclosed
US-20160326158-A1 SULFUR-CONTAINING HETEROCYCLIC DERIVATIVE HAVING BETA SECRETASE INHIBITORY ACTIVITY SHIONOGI & CO (JP) 2016-11-10 US disclosed
US-20160108052-A1 SULFUR-CONTAINING HETEROCYCLIC DERIVATIVE HAVING BETA SECRETASE INHIBITORY ACTIVITY SHIONOGI & CO (JP) 2016-04-21 US disclosed
US-9273053-B2 Sulfur-containing heterocyclic derivative having Beta secretase inhibitory activity SHIONOGI & CO., LTD. (JP) 2016-03-01 US disclosed
US-20150105379-A1 SULFUR-CONTAINING HETEROCYCLIC DERIVATIVE HAVING BETA SECRETASE INHIBITORY ACTIVITY SHIONOGI & CO., LTD. (JP) 2015-04-16 US disclosed
US-8637504-B2 Sulfur-containing heterocyclic derivative having beta secretase inhibitory activity SHIONOGI & CO., LTD. (JP) 2014-01-28 US disclosed
US-20120071475-A1 UREA DERIVATIVES HAVING PI3K-INHIBITING ACTIVITY SHIONOGI & CO., LTD. (JP) 2012-03-22 US disclosed
US-20110230472-A1 RING-FUSED AZOLE DERIVATIVE HAVING PI3K-INHIBITING ACTIVITY SHIONOGI & CO., LTD. (JP) 2011-09-22 US disclosed
US-20110190279-A1 SULFUR-CONTAINING HETEROCYCLIC DERIVATIVE HAVING BETA SECRETASE INHIBITORY ACTIVITY SHIONOGI & CO., LTD. (JP) 2011-08-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160108052-A1 SULFUR-CONTAINING HETEROCYCLIC DERIVATIVE HAVING BETA SECRETASE INHIBITORY ACTIVITY BACE1, BACE2, APP PPARA 1537/4885CYP2C9 2218/4885PTGER1 3258/4885
US-20160326158-A1 SULFUR-CONTAINING HETEROCYCLIC DERIVATIVE HAVING BETA SECRETASE INHIBITORY ACTIVITY BACE1, BACE2, APP PPARA 1663/4885CYP2C9 2216/4885PTGER1 3356/4885
US-20110230472-A1 RING-FUSED AZOLE DERIVATIVE HAVING PI3K-INHIBITING ACTIVITY PIK3R5, PIK3R4, PIK3R1 PPARA 2080/4885CYP2C9 1755/4885PTGER1 4063/4885
US-20150105379-A1 SULFUR-CONTAINING HETEROCYCLIC DERIVATIVE HAVING BETA SECRETASE INHIBITORY ACTIVITY BACE1, BACE2, APP PPARA 1537/4885CYP2C9 2218/4885PTGER1 3258/4885
US-20110190279-A1 SULFUR-CONTAINING HETEROCYCLIC DERIVATIVE HAVING BETA SECRETASE INHIBITORY ACTIVITY BACE1, BACE2, APP PPARA 1537/4885CYP2C9 2218/4885PTGER1 3258/4885
US-20120071475-A1 UREA DERIVATIVES HAVING PI3K-INHIBITING ACTIVITY MTOR, STAT3, SLC14A1 PPARA 2169/4885CYP2C9 3873/4885PTGER1 3988/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.